ING Group’s Ambit Biosciences Corp AMBI Stock Holding History

ING Group’s Portfolio AMBI Stock Details AMBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-50,000	Closed	-$439K	–	725
2014 Q1	$439K	Buy	+50,000	New	+$531K	﹤0.01%	617

Other funds holding AMBI

Foresite Capital Management I Larkspur, California $21.4M AUM 80.48% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ING Group's AMBI Position: Q2 2014 in Review

ING Group sold out of Ambit Biosciences Corp (AMBI) in Q2 2014, closing a stake of 50,000 shares — an estimated $439K sold.

ING Group first reported a position in AMBI in Q1 2014 and held it in 1 quarter. The position peaked at $439K in Q1 2014. 36 funds tracked by Wall St. Rank hold AMBI as of Q2 2014.

ING Group reported no remaining Ambit Biosciences Corp position as of Q2 2014 after selling out during the quarter.
ING Group sold 50,000 Ambit Biosciences Corp shares in Q2 2014, an estimated $439K.
ING Group first reported a position in Ambit Biosciences Corp in Q1 2014 and held it in 1 quarter.
ING Group's Ambit Biosciences Corp position peaked at $439K in Q1 2014.
36 funds tracked by Wall St. Rank held Ambit Biosciences Corp as of Q2 2014.

Based on ING Group's 13F filing for Q2 2014, filed 14 Aug 2014.